Shots:

• Ultragenyx to receive $200m up front including $125M in cash & $75M equity investment at $60/share- $25M on completion of technology transfer the HeLa PCL and HEK293 platforms along with royalties on sales of products manufactured in either system
• Ultragenyx get a non-exclusive license to IP- including know-how and patent applications- regarding its manufacturing technology platforms for AAV-based gene therapy products
• Ultragenyx retains the exclusive right to utilize its manufacturing technology for its current target indications and additional indications identified in the future

Click here ­to­ read full press release/ article 

Ref: Ultragenyx | Image: Ultragenyx